(Q38895586)

7 September 2017

1 reference

title

Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab (English)

1 reference

7 September 2017

0 references

1 reference

1 reference

2

1 reference

7 September 2017

author name string

Konstantinos Leventakos

series ordinal

1

1 reference

7 September 2017

publication date

13 July 2016

1 reference

7 September 2017

1 reference

7 September 2017

volume

30

1 reference

7 September 2017

issue

5

1 reference

7 September 2017

page(s)

397-405

1 reference

https://scigraph.springernature.com/pub.10.1007/s40259-016-0187-0

7 September 2017

exact match

0 references

cites work

Cancer statistics, 2015

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0187-0

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0187-0

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0187-0

Programmed death ligand-1 expression in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0187-0

Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0187-0

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0187-0

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0187-0

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0187-0

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0187-0

Pembrolizumab for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0187-0

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0187-0

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0187-0

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0187-0

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0187-0

Pseudoprogression and Immune-Related Response in Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0187-0

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0187-0

Relationship between progression-free survival and overall survival in patients with advanced non-small cell lung cancer treated with anticancer agents after first-line treatment failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0187-0

Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0187-0

Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0187-0

Statistical Considerations in Clinical Trial Design of Immunotherapeutic Cancer Agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0187-0

B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0187-0

Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0187-0

Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0187-0

Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0187-0

Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Non-Small Cell Lung Cancer to Receive Immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0187-0

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0187-0

Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0187-0

10.1007/S40259-016-0187-0

21 January 2018

Identifiers

DOI

1 reference

7 September 2017

1 reference